Reducing PSA-Based Prostate Cancer Screening in Men Aged 75 Years and Older with the Use of Highly Specific Computerized Clinical Decision Support

被引:23
|
作者
Shelton, Jeremy B. [1 ,2 ]
Ochotorena, Lee [1 ]
Bennett, Carol [1 ,2 ]
Shekelle, Paul [1 ]
Kwan, Lorna [2 ]
Skolarus, Ted [3 ]
Goldzweig, Caroline [1 ]
机构
[1] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA
[3] Vet Adm Ann Arbor Healthcare Syst, Hlth Serv Res & Dev, Ann Arbor, MI USA
关键词
electronic health records; physician decision support; cancer screening; applied informatics; implementation research; quality improvement; HEALTH INFORMATION-TECHNOLOGY; CARE; MORTALITY; ALERTS; INTERVENTIONS; PHYSICIANS; IMPLEMENT; BENEFITS; QUALITY; COSTS;
D O I
10.1007/s11606-015-3249-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In 2012, the Veterans Health Administration (VHA) implemented guidelines seeking to reduce PSA-based screening for prostate cancer in men aged 75 years and older. To reduce the use of inappropriate PSA-based prostate cancer screening among men aged 75 and over. The Veterans Affairs Greater Los Angeles Healthcare System (VA GLA) We developed a highly specific computerized clinical decision support (CCDS) alert to remind providers, at the moment of PSA screening order entry, of the current guidelines and institutional policy. We implemented the tool in a prospective interrupted time series study design over 15 months, and compared the trends in monthly PSA screening rate at baseline to the CCDS on and off periods of the intervention. A total of 30,150 men were at risk, or eligible, for screening, and 2,001 men were screened. The mean monthly screening rate during the 15-month baseline period was 8.3 %, and during the 15-month intervention period, was 4.6 %. The screening rate declined by 38 % during the baseline period and by 40 % and 30 %, respectively, during the two periods when the CCDS tool was turned on. The screening rate ratios for the baseline and two periods when the CCDS tool was on were 0.97, 0.78, and 0.90, respectively, with a significant difference between baseline and the first CCDS-on period (p < 0.0001), and a trend toward a difference between baseline and the second CCDS-on period (p = 0.056). Implementation of a highly specific CCDS tool alone significantly reduced inappropriate PSA screening in men aged 75 years and older in a reproducible fashion. With this simple intervention, evidence-based guidelines were brought to bear at the point of care, precisely for the patients and providers for whom they were most helpful, resulting in more appropriate use of medical resources.
引用
收藏
页码:1133 / 1139
页数:7
相关论文
共 50 条
  • [31] Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer
    Mazzetti, Simone
    Defeudis, Arianna
    Nicoletti, Giulia
    Chiorino, Giovanna
    De Luca, Stefano
    Faletti, Riccardo
    Gatti, Marco
    Gontero, Paolo
    Manfredi, Matteo
    Mello-Grand, Maurizia
    Peraldo-Neia, Caterina
    Zitella, Andrea
    Porpiglia, Francesco
    Regge, Daniele
    Giannini, Valentina
    EUROPEAN RADIOLOGY, 2024, 34 (08) : 5108 - 5117
  • [32] Using prostate specific antigen and prostate specific antigen velocity to determine when to stop prostate cancer screening in men older than 70 years
    Mouraviev, Vladimir
    Mayes, Janice M.
    Sun, Leon
    Moul, Judd W.
    Polascik, Thomas J.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 580 - 580
  • [33] Prostate cancer detection, characterization, and clinical outcomes in men aged 70 years and older referred for transrectal ultrasound and prostate biopsies
    Sung, JC
    Kabalin, JN
    Terris, MK
    UROLOGY, 2000, 56 (02) : 295 - 301
  • [34] The detection rate of clinically insignificant prostate cancer is not increased by PSA-based mass screening: Analysis of low-volume, highly differentiated prostate cancers following TURP
    Wirtenberger, W
    Horninger, W
    Volgger, H
    Klocker, H
    Bartsch, G
    JOURNAL OF UROLOGY, 2002, 167 (04): : 326 - 326
  • [35] PROSTATE SPECIFIC ANTIGEN (PSA)-PYRAMID IN MEN WITH LOW RANGE PSA: PROSTATE CANCER INCIDENCE AND MORTALITY - A PLEA FOR RISK-BASED PROSTATE CANCER SCREENING STRATEGY IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC), AARAU
    Randazzo, Marco
    Seiler, Daniel
    Beatrice, Josef
    Baumgartner, Martin
    Huber, Andreas
    Grobholz, Rainer
    Manka, Lukas
    Ahyai, Sascha
    Chun, Felix
    Recker, Franz
    Kwiatkowski, Maciej
    JOURNAL OF UROLOGY, 2013, 189 (04): : E793 - E793
  • [36] PROSTATE SPECIFIC ANTIGEN (PSA)-BASED SCREENING FOR PROSTATE CANCER IS UNLIKELY A RISK FACTOR TO DETECT CLINICALLY INSIGNIFICANT CANCER IN JAPANESE ELDERLY MEN
    Kojima, Munekado
    Yada, Yasufumi
    Yoshida, Kazuhiko
    Hayase, Yoshimasa
    JOURNAL OF UROLOGY, 2013, 189 (04): : E794 - E794
  • [37] Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2018, 200 (04): : 699 - 699
  • [38] Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy
    Hoffman, Karen E.
    Nguyen, Paul L.
    Ng, Andrea K.
    D'Amico, Anthony V.
    JOURNAL OF UROLOGY, 2010, 183 (05): : 1798 - 1802
  • [39] Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Villers, A.
    Bessaoud, F.
    Tretarre, B.
    Grosclaude, P.
    Malavaud, B.
    Rebillard, X.
    Iborra, F.
    Daubisse, L.
    Malavaud, S.
    Roobol, M.
    Heijnsdijk, E. A.
    de Koning, H. J.
    Hugosson, J.
    Rischmann, P.
    Soulie, M.
    PROGRES EN UROLOGIE, 2020, 30 (05): : 252 - 260
  • [40] Population-based analysis of prostate-specific antigen (PSA) screening in younger men (&lt;55 years) in Australia
    Ranasinghe, Weranja K. B.
    Kim, Simon P.
    Lawrentschuk, Nathan
    Sengupta, Shomik
    Hounsome, Luke
    Barber, Jim
    Jones, Richard
    Davis, Paul
    Bolton, Damien
    Persad, Raj
    BJU INTERNATIONAL, 2014, 113 (01) : 77 - 83